{"id":"NCT00227370","sponsor":"Duke University","briefTitle":"Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation","officialTitle":"A Phase III, Randomized, Double-Blind Comparison of Oral Valganciclovir and Placebo for Prevention of CMV After Lung Transplantation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-07","primaryCompletion":"2008-04","completion":"2008-12","firstPosted":"2005-09-28","resultsPosted":"2013-04-29","lastUpdate":"2024-10-04"},"enrollment":136,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Cytomegalovirus Infections"],"interventions":[{"type":"DRUG","name":"valganciclovir","otherNames":["valcyte"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The study evaluated the efficacy and safety of a prolonged, continuous course of Valganciclovir (Valgan) in the prevention of CMV by comparing 3 months of Vaglanciclovir, the standard of care upon initiation of the study, to 12 months of Valganciclovir.","primaryOutcome":{"measure":"Incidence of CMV End Organ Disease","timeFrame":"over the course of 300 days after randomization","effectByArm":[{"arm":"Placebo Group","deltaMin":21,"sd":null},{"arm":"Treatment Group","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":19},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["39807668","38700045","20547904"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":66},"commonTop":["RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS","GASTROINTESTINAL DISORDERS","LUNG TRANSPLANT REJECTION","OEDEMA PERIPHERAL","FATIGUE"]}}